Indaptus Therapeutics, Inc. (INDP)
INDPNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$3.13
-0.1900 (-5.72%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $480.71m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.9200 to $5.96
- Average volume
- 833.0k
- Previous close
- $3.32
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$2.65m | -$8.16m | -$2.16m | -$1.81m |
| Net income | -$2.98m | -$8.11m | -$2.54m | -$1.79m |
News
8 latest- Biotech Stocks Move Higher - NIVF +25%, ICU +23%, ATRA +11%, INDP +9% RTTNews · Oct 2, 2026
- Biotech Stocks Gain Ground: PDS Biotech, Clene, Indaptus Lead Movers RTTNews · Sep 15, 2026
- 5 Biotech Stocks In Spotlight: Tenon Medical, AEON Biopharma, Silexion, Orchestra BioMed & Indaptus RTTNews · Sep 10, 2026
- Top Biotech Gainers: QURE Rallies On AMT-130 Update, LNAI On Track, FTH Eyes Q4 Data, ELTX On Watch RTTNews · Jun 17, 2026
- Pre-Market Movers: BGMS, CMND, INDP Chart The Course RTTNews · Jun 5, 2026
- Thursday Sector Leaders: Advertising, Biotechnology StocksBNK Invest · Jun 4, 2026
- Top Biotech Gainers: AKTX Rallies; GOVX Up On Ebola Concerns; SLGL Awaits Catalysts; CMMB On Watch RTTNews · May 26, 2026
- Indaptus Therapeutics Enters $6 Million Securities Deal, Appoints David Lazar Co-CEO And Chairman RTTNews · Dec 29, 2025
The company
Indaptus Therapeutics is a biotechnology company dedicated to immunotherapy research. The Company's patented Decoy technology uses attenuated and killed, non-pathogenic Gram-negative bacteria designed to activate multiple components of innate and adaptive immunity while reducing systemic toxicity. The Company is evaluating the Decoy platform and existing therapeutic assets while also assessing complementary research capabilities, strategic investments and potential business combinations. The Company seeks to better understand the relationship among sleep, physical recovery, neurological function and immune status, which could potentially support future immunotherapy evaluation, patient recovery monitoring and biomarker research. The scope and timing of any such activities will depend on scientific validation, strategic fit, market opportunities, available resources, regulatory considerations and other business factors.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- indaptusrx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.